UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 20, 2006 (April 19, 2006)

Endo Pharmaceuticals Holdings Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-15989 (Commission File Number) 13-4022871 (I.R.S. Employer

of incorporation)

Identification No.)

100 Endo Boulevard, Chadds Ford, PA (Address of principal executive offices)

19317 (Zip Code)

Registrant s telephone number, including area code (610) 558-9800 Not Applicable

Former name or former address, if changed since last report

1

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On April 19, 2006, the Registrant announced that executive vice president, chief financial officer and treasurer Jeffrey R. Black intends to retire in August 2006. The Registrant intends to retain a nationally recognized executive search firm to lead the search to replace Black, which will include both internal and external candidates. Black will continue to serve in his role during the search and through a transition period for his replacement. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.	
Not applicable.	
(b) Pro Forma Financial Information.	

(c) Shell Company Transactions

Not applicable.

Not applicable.

(d) Exhibits.

Exhibit Number Description

99.1 Press Release of Endo Pharmaceuticals Holdings Inc. dated April 19, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC. (Registrant)

By: /s/ Caroline B. Manogue Name: Caroline B. Manogue

Title: Executive Vice President, Chief Legal Officer &

Secretary

Dated: April 20, 2006

INDEX TO EXHIBITS

Exhibit No. Description

99.1 Press Release of Endo Pharmaceuticals Holdings Inc. dated April 19, 2006.